For more than 20 years, researchers have known that young-onset Parkinson’s disease is often caused by mutations in the parkin gene, but the exact function of this gene has been hotly debated.
For more than 20 years, researchers have known that young-onset Parkinson’s disease is often caused by mutations in the parkin gene, but the exact function of this gene has been hotly debated.
Chronic pain affects 1 in 5 Canadians, often compromising quality of life, physically, socially, and economically. Pain management is frequently managed with prescription drugs, notably opioids, despite a non-pharmacological, multidisciplinary care approach being recommended as the “gold standard.”
Chronic pain affects 1 in 5 Canadians, often compromising quality of life, physically, socially, and economically. Pain management is frequently managed with prescription drugs, notably opioids, despite a non-pharmacological, multidisciplinary care approach being recommended as the “gold standard.”
Director Dr. Christine Landry shares her vision for uOttawa’s new PharmD program, set to train bilingual pharmacists to contribute to the heightened need for pharmaceutical care within French minority settings.
Director Dr. Christine Landry shares her vision for uOttawa’s new PharmD program, set to train bilingual pharmacists to contribute to the heightened need for pharmaceutical care within French minority settings.
Researchers have treated the first patient in an innovative clinical trial of a cell therapy that aims to prevent very premature babies from developing a chronic lung disease called bronchopulmonary dysplasia (BPD). This is the first trial of its kind in in the world.
Researchers have treated the first patient in an innovative clinical trial of a cell therapy that aims to prevent very premature babies from developing a chronic lung disease called bronchopulmonary dysplasia (BPD). This is the first trial of its kind in in the world.
Researchers have treated the first patient in an innovative clinical trial of a cell therapy that aims to prevent very premature babies from developing a chronic lung disease called bronchopulmonary dysplasia (BPD). This is the first trial of its kind in in the world.
Researchers have treated the first patient in an innovative clinical trial of a cell therapy that aims to prevent very premature babies from developing a chronic lung disease called bronchopulmonary dysplasia (BPD). This is the first trial of its kind in in the world.